Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?
Luiza Raquel GrazziotinGillian CurrieMichelle M A KipMaarten J IJzermanMarinka TwiltRaymond LeeDeborah A MarshallPublished in: PharmacoEconomics (2021)
We have identified critical gaps in the literature reporting HSUV in patients with juvenile idiopathic arthritis including a lack of HSUV measures for distinct health states, particularly in adults with a history of juvenile idiopathic arthritis. The current reported HSUV data in juvenile idiopathic arthritis are insufficient for a full cost-utility analysis with a short or lifetime horizon.